Stockwinners Market Radar for December 07, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:14 EST Cathie Wood's ARK Investment bought 274K shares of Nextdoor today

19:50 EST Instill Bio trading halted, news pending

19:49 EST Seres Therapeutics announces presentation of PK/PD and safety data in SER-155 - Seres Therapeutics "announced that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation will be presented at the 65th American Society of Hematology Annual Meeting held from December 9-12, 2023, in San Diego, California, USA. SER-155 is an oral, cultivated live bacterial consortia investigational therapeutic designed to prevent enteric-derived infections and resulting blood stream infections, as well as reduce the incidence of graft-versus-host disease by modulating immune responses in the gastrointestinal tract."

18:36 EST Supermicro CEO sells $12.6M in common stock - In a regulatory filing, Supermicro disclosed that its CEO Charles Liang sold 50K shares of common stock on December 5th in a total transaction size of $12.6M.

18:26 EST Amazon.com CEO: Have to pay attention to some of the danger of generative AI - In an interview on CNBC's Mad Money, Andy Jassy said generative AI is going to change every customer experience. Generative AI is going to make the company's models better and it's still in early days, he noted. The goal for Alexa is to build the world's best personal assistant, and AI is going to be a big part of that, he added. Jassy is "very bullish" about Amazon's partnership with Hyundai. International is a big business and it's "growing nicely," he said.

17:57 EST Coherus Biosciences announces CFO transition plans - Coherus BioSciences announced that McDavid Stilwell, CFO, has resigned from the company to pursue other opportunities. Stilwell's last day of employment with Coherus will be December 31, 2023, with ongoing service provided beyond that date by mutual agreement. Coherus will appoint a new interim Principal Financial Officer in late December 2023 or early January 2024 while it conducts a search for a new CFO and Principal Financial Officer.

17:47 EST Smith & Wesson Brands falls 6% after Q2 results on 'temporary margin headwinds' - "Although our gross margin continues to be temporarily pressured by fixed-cost absorption, inflationary factors, and inventory reserve adjustments, we strengthened our working capital position by reducing production to drive internal inventory levels down and we anticipate that the temporary margin headwinds will abate in the fourth quarter. We repurchased nearly 646,000 shares during the third quarter, utilizing $8.2M of our $50M authorization, and paid $5.5M in dividends. Consistent with our capital allocation strategy, our board of directors has authorized a 12c per share quarterly dividend, which will be paid to stockholders of record on December 21,with payment to be made on January 4," noted management in a release. Shares are currently down only 4% in after market trade, off of earlier lows.

17:42 EST Monday.com aims to double Annual Contract Value by 2026 - Sees significant untapped expansion opportunity as 61% of Fortune 500 are monday.com customers with the average seat size for Fortune 500 customers at 275 seats and only 10% of the Fortune 500 using either Monday sales CRM or monday dev. Comments taken from investor presentation slides. Reference Link

17:31 EST New Mexico AG sues Meta and Zuckerberg, alleges platform puts kids at risk - Attorney General Raul Torrez filed a lawsuit against Meta Platforms, Chief Executive Officer Mark Zuckerberg, and the company's wholly-owned subsidiaries, including Instagram and Facebook Holdings , to protect children from sexual abuse, online solicitation, and human trafficking. New Mexico AG Torrez said in part: "Our investigation into Meta's social media platforms demonstrates that they are not safe spaces for children but rather prime locations for predators to trade child pornography and solicit minors for sex," said Attorney General Torrez. "As a career prosecutor who specialized in internet crimes against children, I am committed to using every available tool to put an end to these horrific practices and I will hold companies - and their executives - accountable whenever they put profits ahead of children's safety." Reference Link

17:06 EST Vaso to begin trading on Nasdaq via merger with Achari Ventures Holdings I - Vaso (VASO) Vaso plans to uplist from the OTCQX market to the Nasdaq Stock Market via a business combination with Achari Ventures Holdings I (AVHI). Upon the closing of the Transaction, Vaso common stock and warrants are expected to be listed on Nasdaq Capital Market under the ticker symbols "VASO" and "VASOW", respectively. Vaso's common stock will continue to trade on the OTCQX market under the symbol "VASO" until trading on Nasdaq commences following the consummation of the proposed business combination. Vaso CEO Jun Ma will continue to lead the combined company following the proposed business combination. Achari is led by CEO Vikas Desai, who is also Chairman of Achari's Board of Directors. The transaction values Vaso at a pro forma equity value of approximately $176M, at $10.00 per share. The Boards of Directors of Vaso and Achari have each approved the Transaction. The transaction is expected to close in Q1 24.

16:57 EST Saga Communications declares special cash dividend of $2.00 per share - Saga Communications declared a special cash dividend of $2.00 per share. The dividend will be paid on January 12, 2024, to shareholders of record on December 20, 2023. The aggregate amount of the payment to be made in connection with the special dividend will be approximately $12.5M. The special cash dividend will be funded by cash on the company's balance sheet.

16:49 EST Hudson Pacific jumps 8% after appointing Blackstone's Michael Nash to Board - Real estate investment trust Hudson Pacific (HPP) jumped nearly 7% after announcing that Michael Nash,co-founder and Chairman of Blackstone Real Estate Debt Strategies (BX), has been appointed to the company's Board of Directors effective January 1. Shares are up approximately 1% further in the after session to almost 8%.

16:48 EST Marriott Vacations raises quarterly dividend to 76c from 72c per share - The dividend is payable on or around January 4, 2024, to shareholders of record as of the close of business on December 21, 2023.

16:43 EST Supermicro CFO Weigand sells 20,000 common shares - In a regulatory filing, Supermicro Computer CFO David Weigand disclosed the sale of 20,000 common shares of the company on December 5 at a price of $252.175 per share.

16:37 EST Digital Realty, Blackstone announce $7B hyperscale data center development JV - Digital Realty (DLR) and Blackstone(BX) announced that Blackstone-affiliated funds led by Infrastructure, Real Estate and Tactical Opportunities have agreed to establish a joint venture with Digital Realty to develop four hyperscale data center campuses across three metro areas on two continents. The developments are expected to support approximately 500 megawatts of total IT load upon full build out of all campuses. Blackstone will acquire an 80% ownership interest in the joint venture for approximately $700 million of initial capital contributions, while Digital Realty will maintain a 20% interest. Subsequent to closing, the joint venture parties will fund their pro rata share of the remaining development costs. Digital Realty will manage the development and day-to-day operations of the joint venture, for which it will receive customary fees. The four hyperscale data center campuses are located in Frankfurt, Paris and Northern Virginia and have a total estimated development cost of approximately $7B over the course of the next several years. The campuses are planned to support the construction of 10 data centers with approximately 500 MW of potential IT load capacity. Of this capacity, 46 MW is under construction and is 33% pre-leased. The remaining land capacity is in varying phases of pre-construction and is expected to be developed to meet customer demand. Approximately 20% of the total potential IT load capacity is expected to be delivered through 2025, with the balance expected to be delivered in 2026 and beyond. The joint venture is scheduled to close in two stages over the course of the first half of 2024, subject to certain regulatory and other approvals, as well as other customary closing conditions.

16:33 EST Iowa American Water buys City of Donahue's water and wastewater systems - Iowa American Water, a subsidiary of American Water, announced the purchase of the City of Donahue's water and wastewater systems for $1.75M. The acquisition, which will add 140 water and 118 wastewater customers to the company's Quad Cities service area, was approved by the Iowa Utilities Board in Des Moines on July 20, 2023. "Iowa American Water is excited to expand our services and directly serve our new customers in Donahue," said Randy Moore, president of Iowa American Water. "Since 2020, we have had the privilege of partnering with Donahue to operate and maintain the city's water treatment plant to provide clean, safe, and reliable drinking water to the community. We appreciate the City's trust and confidence in our team of water and wastewater professionals."

16:32 EST Avid Bioservices drops 23% after Q2 results, reduced FY24 revenue - Shares are down $1.20 per share or 23% to $4.10 per share in after market trading after disclosing that Q2 revenues were impacted by a number of factors, requiring a decrease in the company's revenue view for FY24.. "Despite the challenges of the first half of fiscal 2024, our current backlog and pipeline position us well to generate cash from operations in the near term, and significant growth in the medium-term and beyond. For these reasons, we believe the second half of the year holds great promise and opportunity for Avid."

16:31 EST Spotify announces CFO transition effective March 31, 2024 - Spotify Technology "announced its Chief Financial Officer, Paul Vogel will be leaving the company on March 31, 2024. The company has launched an external search for his successor. In the interim, Ben Kung, Vice President of Financial Planning and Analysis, will take on expanded responsibilities to support the company's realignment of its financial leadership team."

16:30 EST Ecolab raises quarterly dividend 8% to 57c per share - The board of directors of Ecolab declared an 8% increase in the company's quarterly cash dividend to 57c per common share, to be paid January 16, 2024, to shareholders of record at the close of business on December 19, 2023. This increase results in a new indicated annual cash dividend of $2.28 per share in 2024 and represents Ecolab's 32nd consecutive annual dividend rate increase. Ecolab has paid cash dividends on its common stock for 87 consecutive years. Commenting on the increase, Christophe Beck, Ecolab's Chairman and Chief Executive Officer said, "The robust growth in Ecolab's cash dividend reflects our strong business momentum heading into 2024, excellent cash flow, and our commitment to returning to historical dividend payout ratio levels. We remain committed to enhancing total shareholder returns through strong growth in our business and attractive cash dividends."

16:25 EST CubeSmart increases quarterly dividend 4.1% to 51c per share - CubeSmart announced that its board of trustees declared a quarterly dividend of 51c per common share for the period ending December 31. The dividend is payable on January 16, 2024 to common shareholders of record on January 2, 2024. The quarterly distribution represents an annualized dividend rate of $2.04 per share, an increase of 8c per share from the previous annual rate of $1.96 per share.

16:20 EST Broadcom reports Q4 cash from operations $4.83B, free cash flow $4.72B

16:19 EST Universal Health Realty increases dividend 0.5c to 72.5c per share - Universal Health Realty increased the quarterly dividend by 0.5c and pay a dividend of 72.5c per share on December 29, 2023 to shareholders of record as of December 19.

16:18 EST Rocket Lab signs deal to launch South Korean satellite - Rocket Lab USA announced it has signed a launch services agreement to launch an Earth observation satellite for the Korea Advanced Institute of Science and Technology on a rideshare mission in the first half of 2024. KAIST's NeonSat-1 will be the primary payload on an Electron rideshare mission that will also deploy NASA's Advanced Composite Solar Sail System, or ACS3 satellite. The mission will lift-off from Rocket Lab Launch Complex 1 in New Zealand. "2024 is shaping up to be our busiest launch year yet with a fully booked manifest of Electron missions," said Rocket Lab founder and CEO, Peter Beck. "By combining this mission with the launch of NASA's ACS3 spacecraft, we've been able to provide KAIST with a launch opportunity on short notice to help them reach orbit faster. It's a privilege to be working with the KAIST team and we are thrilled to be providing them with timely and affordable launch services on Electron."

16:17 EST RH falls 5% to $267.00 after Q3 earnings miss, reduced operating margin guide

16:15 EST Avid Bioservices reports revenue backlog was $199M as of October 31 up 35% - As of October 31, company's revenue backlog was $199M, representing an increase of 35% compared to $147M at the end of the same quarter last year. The company expects a growing portion of its backlog will extend beyond a year.Avid reported cash and cash equivalents on October 31, 2023, of $31.4 million, compared to $38.5 million on April 30, 2023. The second quarter cash and cash equivalents balance represents a 26% increase compared to $24.9 million at the end of the first quarter of fiscal 2024.

16:13 EST Torrid names Paula Dempsey CFO - Torrid Holdings announced the promotion of Paula Dempsey to the role of Chief Financial Officer. Dempsey served as the interim CFO until her promotion on December 4, 2023. Dempsey joined the company in January 2023 and has been serving as interim CFO and Senior Vice President and Investor Relations since May 2023. Dempsey has extensive retail experience and has held senior leadership roles in publicly-held companies in finance and financial planning and analysis. She was Senior Vice President of Corporate Finance at Mattress Firm prior to joining Torrid. Lisa Harper, Chief Executive Officer, stated, "I am delighted to announce that after an extensive search, we have chosen Paula as our new CFO. She has proven herself as a strong leader and a great partner to me and our entire executive team. I am confident that Paula is the right person to lead our finance organization."

16:10 EST DocuSign reports Q3 adjusted gross margin 83% - Net cash provided by operating activities was $264.2M compared to $52.5M in the same period last year. Free cash flow was $240.3M compared to $36.1M in the same period last year.

16:06 EST Black Mountain Acquisition Corp trading halted, news pending

16:00 EST Primoris receives projects valued over $800M - Primoris Services Corporation announced it received several awards with a combined value over $800M secured by the company's Energy Segment, including more than $300M for engineering, procurement and construction of utility-scale solar projects. "We continue to realize opportunities in our solar and industrial end markets based on long-standing customer relationships as well as the reputation and expertise of our project teams' capabilities to successfully execute on clients' projects," said Tom McCormick, President and Chief Executive Officer of Primoris. "These awards add to our already record 2023 in winning new work and include a mix of projects such as upgrades to natural gas facilities, renewable fuels production and solar power generation for both new and existing customers. I want to applaud our teams' diligence in securing these awards that extend our backlog into 2026." The projects are scheduled to begin engineering and mobilization the fourth quarter of 2023 and early 2024.

14:32 EST Robinhood launches crypto trading in the EU, with customer bonuses - Earlier on Thursday U.S.-based financial services platform, Robinhood (HOOD), blogged in part:"... we are launching the Robinhood Crypto app to all eligible customers in the European Union EU. It is the only custodial crypto platform where customers will get a percentage of their trading volume back every month, paid in Bitcoin BTC, and can get up to 1 BTC when they sign up and refer a friend. Robinhood Crypto offers buy and sell support for 25+ cryptocurrencies with industry-leading safety and security. It is the lowest cost crypto trading platform in the EU on average. "We believe crypto is the financial framework for tomorrow and that it plays a significant role in our mission to democratize finance for all," said Johann Kerbrat, GM of Robinhood Crypto. "For this reason, we're thrilled to expand crypto trading to customers throughout the EU, enabling them to buy and sell their favorite tokens safely and securely. The EU has developed one of the world's most comprehensive policies for crypto asset regulation, which is why we chose the region to anchor Robinhood Crypto's international expansion plans....In addition to being the lowest cost crypto trading platform in the EU on average, customers will earn a percentage of every trade back each month, which is paid out in Bitcoin and deposited directly into customer accounts. The amount of BTC paid out is based on the total volume traded in a given month-customers can learn more about this program and can see how much they could receive by visiting the help center." Other symbols exposed the news in crypto trading include: BITCOIN, $ETH, $LTC (RIOT), Marathon Digital (MARA), Coinbase (COIN), MicroStrategy (MSTR), Bitcoin Investment Trust (GBTC). Reference Link

13:44 EST AMD says 'very confident' in guidance for over $2B in MI300 revenue in 2024 - AMD executives, speaking at the Barclays Global Technology Conference about yesterday's launch event for the MI300A and MI300x, "highlighted the advantage we have" given the "industry-leading memory bandwidth and capacity," calling it "a great product, very competitive." The company noted that during its last earnings call it had said MI300 will be the fastest revenue growth product in dollars in its history, adding "we are very confident" in the "revenue number we talked about" for 2024. During yesterday's event, AMD had reiterated its expectation of over $2B in MI300 revenue in 2024.

13:37 EST Expion360 Inc trading halted, volatility trading pause

13:01 EST Chanson International Holding trading resumes

12:46 EST Teradata down 7% as company presents at Barclays conference - Shares of Teradata are down $3.26, or 7%, to $43.03 as of 12:45 pm EST. Executives are speaking at the Barclays Global Technology Conference and have given comments about deal cycles elongating and deals potentially being pushed out.

12:27 EST NWTN Inc. announces strategic partnership with CSCEC - NWTN Inc. announced a landmark Memorandum of Understanding with China State Construction Engineering Corporation LLC, or CSCEC. Under the terms of the MOU, CSCEC will manage the comprehensive project construction process, including planning, feasibility studies, general contracting, and project financing assistance. In parallel, NWTN will focus on project investment and operations, harnessing its market and product advantages to boost the sales and market expansion of new energy vehicles and green hydrogen projects.

12:00 EST Methode Electronics falls -12.2% - Methode Electronics is down -12.2%, or -$2.97 to $21.42.

12:00 EST Sprinklr falls -31.5% - Sprinklr is down -31.5%, or -$5.25 to $11.45.

12:00 EST Grupo Supervielle rises 7.4% - Grupo Supervielle is up 7.4%, or 26c to $3.75.

11:39 EST Boeing dips as Reuters reports on delay to 737 production ramp-up

11:06 EST Kedrion announces eight-year extension of distribution agreement with Kamada - Kedrion Biopharm announces the execution of a binding memorandum of understanding with Kamada for the amendment and the 8-year extension of the KEDRAB US distribution agreement between the two companies. KEDRAB is a Human Rabies Immune Globulin developed in partnership with Kamada. Kedrion started the distribution of this product in the US in 2018. This new commercial agreement, which begins in January 2024, includes potential expansion of Kedrion's distribution of KEDRAB in additional territories beyond the US. In addition, the two companies will collaborate to expand distribution of Kedrion products by Kamada in Israel.

10:18 EST Golden Heaven Group Holdings Ltd trading resumes

10:08 EST Golden Heaven Group Holdings Ltd trading halted, volatility trading pause

10:06 EST Block announces global launch of self-custody bitcoin wallet Bitkey - Bitkey, the self-custody bitcoin wallet built by Block, launched in more than 95 countries across six continents, widening access to self-custody and empowering people around the world to truly own and manage their bitcoin easily and safely. Today, the vast majority of the millions of bitcoin owners keep their bitcoin in the custodial platforms or exchanges where they bought it, leaving them under the control of the custodian. Accessing self-custody solutions where people can truly own the keys to their bitcoin still often relies on a complex set of devices or long passwords that people need to remember to be able to recover their money in case of loss. Bitkey includes a mobile app, hardware device, and a set of recovery tools in case the customer loses the phone, their hardware, or both. Built by the Proto team at Block, Bitkey is now available for pre-orders at bitkey.world, with shipping starting in early 2024.

10:03 EST Textron enters agreement with ATP Flight School for 40 Cessna Skyhawks - Textron Aviation announced an agreement with ATP Flight School for the purchase of an additional 40 Cessna Skyhawk aircraft to be delivered beginning in 2026. This addition to ATP's existing fleet of nearly 225 Skyhawks, deployed across more than 85 training centers nationwide, will provide students with access to a modern and advanced fleet in support of their pilot career aspirations This agreement marks the fourth fleet purchase, amounting to a total of 135 of Cessna Skyhawks, for ATP's Airline Career Pilot Program in just over a year, as the flight school scales to train 20,000 airline pilots by 2030.

10:00 EST Global Indemnity falls -21.7% - Global Indemnity is down -21.7%, or -$7.36 to $26.60.

10:00 EST PHX Minerals rises 4.6% - PHX Minerals is up 4.6%, or 15c to $3.36.

10:00 EST 3D Systems rises 6.7% - 3D Systems is up 6.7%, or 37c to $5.91.

09:48 EST Curiosity Ink Media's Santa.com partners with American Greetings - Curiosity Ink Media and its e-commerce platform, Santa.com have reached an agreement with American Greetings to offer holiday-related products in its highly trafficked Gift Shop. Available now for purchase, American Greetings' popular digital Jacquie Lawson Edwardian Advent Calendar is an annual favorite for all age groups.

09:47 EST Duckhorn Portfolio falls -10.8% - Duckhorn Portfolio is down -10.8%, or -$1.10 to $9.11.

09:47 EST SQM rises 4.1% - SQM is up 4.1%, or $2.02 to $51.63.

09:47 EST 3D Systems rises 8.9% - 3D Systems is up 8.9%, or 49c to $6.04.

09:40 EST MicroAlgo Inc trading resumes

09:35 EST MicroAlgo Inc trading halted, volatility trading pause

09:31 EST Cadiz says Susan Kennedy to step into CEO role on January 1, 2024 - Cadiz is pleased to announce that Susan Kennedy, Executive Chair of the Board of Directors, will step into a full-time role as the company's CEO beginning January 1, 2024. Scott Slater, who has served as President and CEO of Cadiz since 2011, plans to continue to serve as a senior advisor to the company. The company also plans to create two new executive positions in 2024, one focused on development and operation of the Cadiz Water Supply and Storage Project and one focused on scaling the Company's wholly owned water filtration business, ATEC Water Systems.

09:26 EST Siyata Mobile receives $900,000 follow-on order - Siyata Mobile has received a $900,000 order for existing international Defense and EMS customers for the Company's UV350 In-Vehicle device, and its PTT rugged handsets. The order is expected to be delivered during the fourth quarter of 2023 and the first quarter of 2024

09:25 EST Atlantic Union Bankshares to pay $1.2M, refund $5M in fees in CFPB settlement - Atlantic Union Bank, a subsidiary of Atlantic Union Bankshares, announced it has settled an investigation by the Consumer Financial Protection Bureau, or CFPB, into certain practices of Atlantic Union during the period from 2017 to 2020 relating to its opt-in overdraft privilege service. As part of the settlement, Atlantic Union will pay a civil penalty of $1.2M and will refund at least $5M in fees to impacted customers. Atlantic Union does not admit to any wrongdoing, past or present, under the settlement. The CFPB's allegations underlying the settlement relate to the disclosure and enrollment procedure followed by Atlantic Union when enrolling customers in Atlantic Union's Opt-In Overdraft Privilege service by telephone or in branches during the period from 2017 through portions of 2020.

09:20 EST Thermon Group appoints Victor Richey to board of directors - Thermon Group Holdings (THR) announced the appointment of Mr. Victor Richey, retired Chairman and CEO of ESCO Technologies, Inc (ESE), to Thermon's board of directors. Mr. Richey's addition is part of the Board's ongoing succession planning efforts.

09:13 EST SoundHound acquires SYNQ3 to expand AI customer service, no terms - SoundHound announced a definitive merger agreement to acquire SYNQ3 Restaurant Solutions, a leading provider of voice AI and other technology solutions to the restaurant industry. The deal will make SoundHound the preeminent U.S. provider of voice AI for restaurants, significantly extending its market reach by an order of magnitude to over 10,000 signed locations and accelerating the deployment of leading-edge generative AI capabilities to the industry. SYNQ3 will add large brands spanning drive thru, fast casual, casual segments, and convenience stores to SoundHound's fast growing customer base - bringing the total to more than 25 national and multinational chains. The highly complementary businesses will match nearly two decades of SoundHound AI innovation with decades of SYNQ3 industry expertise and established relationships. The SYNQ3 team brings deep restaurant sales, product, and customer service experience with an increasing focus on AI. Seasoned executive talent like CEO and Co-Founder Steve Bigari, a former McDonald's operator, will strengthen SoundHound AI's leadership as the company moves to rapidly roll out its best-in-class proprietary AI solutions to restaurants across the U.S. and beyond.

09:11 EST Sutton Wealth to join Focus partner firm Cornerstone Wealth Group - Focus Financial Partners entered into a definitive agreement under which Sutton Wealth Advisors will join Focus partner firm Cornerstone Wealth Group. This transaction is expected to close in the first quarter of 2024, subject to customary closing conditions. Founded in 2007 by Ed Sutton, Sutton Wealth is a Tampa, FL based wealth management firm with a focus on financial and estate planning. The firm predominantly serves Florida based high net worth individuals and families. This transaction enables Sutton Wealth clients to benefit from Cornerstone's bench of talent and operational scale while Cornerstone adds a quality team with deep planning capabilities in a fast growing market.

09:10 EST Matterport announces 3D digital twin of Germany's Kramerbrucke bridge - Matterport was used to produce a 3D digital twin of one of the oldest and longest continuously inhabited bridges in the world, the Kramerbrucke, located in the city of Erfurt, in Thuringia, Germany.

09:08 EST EF Hutton Acquisition I opens window for stockholder redemption reversals - EF Hutton Acquisition Corporation I provided an update regarding stockholder redemptions. On December 5, 2023, the Company's public stockholders holding 3,470,945 shares, out of a total of 3,492,647 shares of common stock held by public stockholders, submitted requests to redeem their public shares for a pro rata portion of the trust account holding proceeds from the Company's initial public offering in connection with the stockholder vote for the in connection with the Company's meeting of stockholders scheduled for December 7, 2023 at 10:30 a.m. Eastern Time. The Meeting was called to have stockholders approve the Company's planned business combination with Humble Imports Inc. d/b/a ECD Auto Design. As a result of the redemption requests there currently are approximately 21,702 shares of common stock held by public stockholders. As of November 30, 2023, there was approximately $38,239,170 in the Trust Account. Based upon the amount in the Trust Account as of November 30, 2023, the Company estimates that the per share redemption price, assuming withdrawals from income earned on funds in the Trust Account to pay franchise and income taxes owed by the Company will be approximately $10.75. The Company will be accepting requests by any such redeeming public stockholders to withdraw their previously submitted redemption requests until 12:00 p.m. Eastern Time on December 8, 2023.

09:07 EST Nuvve Holding achieves record month and quarter charging station deployments - Nuvve Holding achieved another record month in November for the addition of chargers connected to its V2G GIVe software platform, with the addition of 43 AC and DC bidirectional charging station connections which represents 1.42 MW of additional capacity. Through the first two months of Q4 2023 Nuvve added 81 chargers to its proprietary vehicle-to-grid platform, vs. 18 chargers deployed for the first two months of Q4 2022, an increase of 350%. With one month remaining in Q4 2023, Nuvve has already surpassed its prior quarterly record for chargers added to its V2G GIVe software platform. Year to date through November 2023, megawatts under management have increased by 39% to 24.2.

09:05 EST Wolters Kluwer integrates GenAI into its legal research products - Wolters Kluwer Legal & Regulatory today announced an innovative feature for legal professionals: Generative Pre-training Transformer-generated summaries of court rulings. GPT summarization harnesses generative AI to simplify legal research, eliminating the need to read through multiple court cases, saving valuable time. This innovation in beta will initially serve legal professionals using the Wolters Kluwer Online research platform in Germany before being rolled out to other products. Martin O'Malley, CEO of Wolters Kluwer LR, said: "We recognize our customers' need for efficiency and accuracy in legal research. With the integration of GPT-generated summaries into our legal research products, we're transforming the way in which legal professionals assess and interpret case law. This innovative feature is a testament to our commitment to empowering our customers with our deep domain knowledge, the highest editorial quality and the latest in GenAI technology, ensuring they remain at the forefront of the legal field."

09:04 EST Viemed Healthcare announces voluntary delisting from TSX - Viemed Healthcare announced that it has applied and received approval from the Toronto Stock Exchange for the voluntary delisting of its common shares from the TSX. The delisting from TSX will not affect the Company's listing on the NASDAQ Capital Market. "The Company is taking strategic action to enhance market efficiency and optimize our administrative processes by consolidating trading volumes on NASDAQ, as the majority of both outstanding shares and trading volume is currently concentrated in the United States. The delisting from TSX will create a singular focal point and central marketplace for the Company's common shares, contributing to increased long-term liquidity on NASDAQ and increased shareholder value." said Viemed Chief Operating Officer, Todd Zehnder. The Common Shares will be delisted from TSX effective as of close of markets on December 21, 2023.

09:04 EST UBS, Credit Suisse enter into definitive merger agreement - Following the merger of the holding companies UBS Group AG and CS Group AG on June 12, 2023, the Board of Directors of UBS Group AG has approved the execution of a merger of UBS AG and Credit Suisse AG. Following approvals from their respective Boards, both entities have entered into a definitive merger agreement. The completion of the merger is subject to regulatory approvals and is expected to happen in 2024. Separately, UBS continues to prepare for the planned merger of UBS Switzerland AG and Credit Suisse AG also in 2024. In connection with the planned merger, UBS AG is filing with the US Securities and Exchange Commission a Form 6-K containing unaudited pro forma condensed financial information giving effect to the merger.

09:03 EST AppFolio selected by AMC as technology partner to drive future expansion - AppFolio announced that it recently welcomed property management firm Advanced Management Company, AMC, to its growing roster of customers using AppFolio Property Manager Plus. This partnership underscores AppFolio's commitment to building innovative, customizable solutions for large property management firms. AMC selected AppFolio due to its comprehensive property management solution, which includes AppFolio Realm, and its suite of AI solutions that covers Realm-X, a conversational interface powered by Generative AI for the real estate industry. These innovations, coupled with advanced insights, reporting tools, and user-friendly dashboards, offer high-growth, large-scale property management firms the reliability and efficiency necessary for smooth, strategic portfolio management.

09:02 EST 10x Genomics collaborates with NIH CARD on neuroscience research - 10x Genomics announced a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias to build a more comprehensive single cell atlas of the human brain to further neuroscience research. Known for complementing a broad range of NIH-funded research that requires harnessing emerging technologies at scale, NIH CARD will use Chromium Single Cell Multiome to profile the epigenome and whole transcriptome across millions of individual cells from ancestrally diverse brain samples.

09:02 EST Cogent Biosciences presents new preclinical data on ErbB2, PI3Kalpha programs - Cogent Biosciences presented updated preclinical data from its potent, selective and brain penetrant ErbB2 inhibitor program along with initial preclinical data from its newly disclosed H1047R mutant-selective PI3Kalpha inhibitor discovery program at the 2023 San Antonio Breast Cancer Symposium, taking place December 5-9, 2023 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. "Broadening our pipeline of potential best-in-class targeted therapies remains key to our long-term strategy, and we are excited to provide an update on our selective, EGFR-sparing ErbB2 inhibitor, which features exceptional potency, half-life and oral bioavailability with potentially best-in-class brain penetrance to enable inhibition of mutations in CNS tissue," said Andrew Robbins, Cogent's President and Chief Executive Officer. "In addition, we are pleased to present initial data on our effort to design a potent H1047R mutant-selective PI3Kalpha inhibitor. This program aligns with our mission of creating best-in-class targeted therapies for patients with genetically defined diseases and is complementary to our efforts focused on the development of bezuclastinib in advanced and nonadvanced systemic mastocytosis and GIST."

08:55 EST Edwards Lifesciences approves $1B of additional share repurchase authorization - Edwards announced that the board of directors approved $1B of additional share repurchase authorization. "This is consistent with past practice of the board of directors authorizing additional amounts under the share repurchase program when prior authorizations near completion," the company stated in conjunction with its annual investor conference.

08:53 EST Ciena sees FY24 gross margin in mid-40% range - Sees adjusted operating expense about $355M per quarter in FY24.

08:50 EST Ciena targeting adjusted operating margin of 15%-17% for FY26

08:49 EST Ciena sees average annual revenue growth of 6%-8% for FY26-FY26

08:42 EST Luna secures large, multi-unit follow-on order under agreement with Northrop - Luna Innovations (LUNA) Incorporated announced that it has extended its existing relationship with Northrop Grumman (NOC) by securing a new, multi-unit, multi-million dollar order for its OBR 6200 portable backscatter reflectometer. The order was placed under the auspices of the multi-year agreement the company announced last December. "The longevity and success of our relationship with Northrop Grumman is a testament to the value and criticality of our products and what they bring to the defense sector on a global scale," said Scott Graeff, President and Chief Executive Officer of Luna. "Luna has a long history of working in close collaboration with our partners to provide advanced solutions based on our market leading position in fiber optic diagnostics and sensing. We are honored to work with our partner Northrop Grumman to enhance our national defense by supporting the global fleet of F-35 aircraft." Under the structure of the multi-year agreement between the two companies, Northrop Grumman places annual orders for supply of test systems under pre-negotiated pricing, simplifying the transaction and resulting in more efficient use of resources. As Luna has reported previously, the OBR 6200 instrument is included with the sustainment equipment when F-35s are deployed globally.

08:39 EST Sidus Space gets ASTRA Flight equipment on LizzieSat ahead of Q1 SpaceX launch - Sidus Space announced that it has received its ASTRA or Autonomous Satellite Technology for Resilient Applications, Flight Software Version 1.0 and ASTRA flight hardware from NASA Stennis and installed it on the Company's LizzieSat satellite ahead of its first quarter 2024 SpaceX Transporter 10 launch. NASA Stennis has completed its Flight Readiness Review in preparation for the 2024 launch and will be one of six payloads aboard LizzieSat. In preparation for the next operational phase of on-orbit testing, ASTRA software has been loaded onto ASTRA Flight Hardware and delivered to Sidus for installation aboard LizzieSat. When the satellite launches in 2024, the NASA Stennis Autonomous Systems Laboratory team will send targeted satellite operations commands for its ASTRA Flight Software to perform via the Sidus flight computer. The initial version of the software includes vehicle systems management capabilities, as well as the ability to update software versions and add capabilities during the mission, which could last more than two years.

08:38 EST Ciena entering FY24 confident in ability to grow faster than market

08:36 EST Safety Shot appoints Pascucci to board of directors - Safety Shot announced Rich Pascucci, who has been serving on the Company's Advisory Board, has joined its Board of Directors. Pascucci brings a wealth of leadership experience in the beverage industry. He has held leadership and C-suite roles driving portfolio growth for global companies. Currently, he is the owner of Black Apple Group, where he specializes in insights, category development, integration, and planning.

08:36 EST Bsquare Corp's acquisition by Kontron completed - Bsquare and Kontron, a global IoT Technology company, announced the successful completion of the tender offer by Kontron Merger Sub, a wholly owned, indirect subsidiary of Kontron, to acquire all of the outstanding shares of common stock of Bsquare for $1.90 per Share, net to the seller in cash. Approximately 70.9% of the total outstanding Shares were tendered, and an additional 386,424 Shares were tendered pursuant to guaranteed delivery procedures, representing an additional approximately 1.9% of total outstanding Shares. The parties expect to consummate the merger on or about December 7. Remaining outstanding shares will be converted into the right to receive $1.90 per share. As a result of the offer and the merger, Bsquare will become a wholly-owned, indirect subsidiary of Kontron and Bsquare common stock will cease trading on NASDAQ.

08:35 EST Edwards Lifesciences to spin-off Critical Care at end of 2024 - Edwards Lifesciences intends to complete a tax-free spin-off of Critical Care at the end of 2024, the company announced. "The planned separation will enable sharpened focus as Edwards pursues expanded opportunities for TAVR, TMTT and Surgical patients, as well as new investments in interventional heart failure technologies," the company stated. "We are proud of the Critical Care team, its rich legacy of pioneering innovation and the contributions they have made to our company, and we look forward to an even stronger future for Critical Care," said Zovighian. "The spin-off will enable Critical Care to have increased focus and flexibility to build upon its global leadership position in advanced patient monitoring, transforming care through AI-enabled smart monitoring solutions while expanding its reach to millions of patients around the world. Katie Szyman, Corporate Vice President of Critical Care since 2015, will be Chief Executive Officer of the new company upon completion of the transaction. More information regarding the planned spin-off will be provided during the course of 2024, and the company is planning a mid-year SEC Form 10 submission," Edwards added.

08:34 EST Bitdeer mined 403 bitcoin in November - Bitdeer Technologies Group announced its unaudited mining and operations updates for November 2023. bitcoin mined: 403; Total has rate under management: 21.1 EH/s; mining machines under management 220,000. Linghui Kong, Chief Executive Officer of Bitdeer, commented, "During November, our core business performed steadily and new growth opportunities emerged. Importantly, we became a Preferred Cloud Service Provider in the NVIDIA Partner Network, and announced our plans to launch Bitdeer AI Cloud, a cloud service powered by NVIDIA's DGX SuperPOD systems. Bitdeer AI Cloud will be among the first cloud services in Asia to be powered by cutting-edge DGX H100 systems. We anticipate that the service will launch in the first quarter of 2024, and we expect expanding demand for generative AI capabilities to fuel its success... On the infrastructure front, our 175MW immersion cooling datacenter at our Tydal mining facility in Norway remains on course for completion in 2025. Looking ahead, we will continue to advance our long-term initiatives and prudently execute our operational strategies to generate sustainable shareholder value."

08:33 EST Gorilla announces operational, financial update - Gorilla Technology Group updated investors on operating and financial progress. Business Highlights: Strong cash flow from operations with receipt of over $25 million in milestone payments from new projects. Achieved material top-line growth driven by project advancements. Continuous improvement achieved in operational efficiencies. Announced $25 million registered direct offering of convertible preferred stock. Operational Highlights: Established partnerships with industry leaders such as Redhat, Lanner, Protactic, Infosec Global, and GST, enhancing overall capabilities. In a rapidly evolving industry, introduced AI based investigation products iCCTV and Post Event, a new Cyber Security Operations Management solution and service, each pushing the boundaries of what's possible to meet the continually evolving customer needs. Implemented effective cost optimization strategies, accelerating movement toward profitability and boosting competitive advantage. Steadily ramping sales and marketing efforts in Taiwan, Thailand, India, UK, Latin America, Middle East and North Africa, building visibility toward a strong sales pipeline of over $1 billion.

08:23 EST Lear: Q4 shaping up 'about how we expected,' sees revenue 'a bit' above guidance - Sees revenue "a bit above our initial guidance" for Q4 and the full year. Comments taken from the Goldman Sachs 15th Annual Industrials & Autos Week Conference.

08:22 EST GM, Autocar collaborate on zero tailpipe emissions commercial vehicles - General Motors and Autocar Industries have signed a joint development agreement to create a range of zero tailpipe emissions vocational vehicles powered by GM's HYDROTEC power cubes. Autocar views this initiative as an important expansion in offering robust, zero tailpipe emissions solutions to customers. Fuel cell technology offers an additional energy propulsion option to support Autocar's vocational customers' move toward EPA requirements. Hydrogen fuel cells are a key component of GM's electrification strategy which extends beyond battery-powered passenger vehicles. Since fuel cells are lightweight and enable large payloads, excellent range, quiet operation and rapid refueling, they can meet the needs of the heaviest duty applications. These jointly developed trucks will be powered by GM's HYDROTEC power cubes, which are GM's fuel cell propulsion system solution for these very demanding commercial vehicles. The first of these vehicles is expected to go into production in 2026 at the Autocar Truck Plant in Birmingham, Alabama. Vehicles with HYDROTEC technology will be built to order by Autocar and will be sold directly to customers.

08:21 EST Dominion Lending Centres appoints Dave Teixeira as EVP, DLCG operations - Dave Teixeira, currently Executive Vice President, Business Development and Public Affairs, has been appointed Executive Vice President, DLCG Operations

08:20 EST ABM expands partnership with LaGuardia Gateway Partners - ABM announces the expansion of its relationship with LaGuardia Gateway Partners, LGP, the developer and manager of LaGuardia Terminal B, to provide comprehensive integrated facility services and best-in-class traveler experiences at Terminal B. Following LGP's historic and award-winning redevelopment of Terminal B, ABM has been selected by LGP to provide a "one team" approach for comprehensive facility operations and services, with the goal to provide a safe, seamless, and consistent experience for guests, while driving long-term asset preservation, efficiency, sustainability, and diversity across the 1.3 million square foot facility. This collaboration with LGP will optimize and unify operational efficiency across Terminal B. Managing more than 700 team members serving the Terminal, ABM's Performance Solutions team will work to improve the sustainability of the Terminal's operations and the diversity of its suppliers. "The redevelopment of Terminal B was intentionally designed to delight passengers at every touchpoint from curb to gate and ABM is the perfect partner to complement our best-in-class experience with a commitment to innovation and delivering excellence for unparalleled guest and partner experiences," said Jamie Haviaris, Chief Technical Officer at LaGuardia Gateway Partners. "Our partnership with ABM played a key role in the success of the new Terminal B, and we are pleased to have them deliver that same methodology across additional functions of the Terminal."

08:18 EST Wearable Devices announces strategic expansion in North America - Wearable Devices has announced a strategic expansion in North America with the establishment of a new U.S. office in Redwood City, California. This significant move is set to amplify the Company's presence and foster stronger relationships with partners in the rapidly growing wearables market. "Our expansion into Silicon Valley is a game-changer," says Asher Dahan, Chief Executive Officer of Wearable Devices. "It's more than just about geographical presence; it's about being at the epicenter of technology and innovation. This move aligns perfectly with our mission to revolutionize how people interact with technology."

08:17 EST Save Foods targeting U.S. carbon credit market with Nitrousink - Save Foods previously entered the carbon credit and greenhouse gas emissions markets, following its acquisition of a majority stake in the newly-formed Nitrousink, a research and development company using technologies developed at the Agricultural Research Organization - Volcani Institute, under the leadership of Dr. Dror Minz, PhD in Environmental Microbiology, and the Director of the Institute of Soil, Water and Environmental Sciences at the Volcani Institute. Nitrousink's research is based on a deep understanding of plant root microbiome structure and function. Its solution tailors the natural root microbiome, to improve the abundance and function of naturally occurring novel nitrous oxide and reduce bacteria to minimize the emission of this highly potent greenhouse gas. Nitrousink's R&D demonstrated positive results identifying and isolating two bacteria species from wheat roots. In a novel discovery, Dr. Minz found these bacteria are naturally capable of reducing N2O emissions under various environmental conditions. One of the bacteria is active under oxygen conditions and reduces emissions by 44%, while the other reduces emissions by 39% under oxygen-depleted conditions. The two bacteria species were grown in a lab and later successfully introduced to greenhouse wheat samples. The implications of these findings appear to be profound and offer a potential way to cut N2O emissions given that approximately 73% of man-made N2O emissions entering the atmosphere are a result of agricultural soil management. Save Foods will fund Nitrousink's research and development and commercialization efforts in an amount of up to $1.2 million over three years, primarily to allow for the expansion and widespread implementation of this innovative technology.

08:15 EST FTC Solar appoints Anthony Carroll as chairman of Customer Advisory Board - FTC Solar has formed a Customer Advisory Board to support growth and a world-class customer experience, and has named renewables expert Anthony Carroll as its inaugural Chairman. The advisory board will serve as a valuable resource to support company growth from pipeline development through purchase order. Consistent feedback will also ensure the company provides increasingly valuable solutions for customers with a product strategy and roadmap that best aligns with evolving needs in the marketplace. The formation of the FTC Solar advisory board is a testament to the company's long-term commitment to a customer-first strategy, which has contributed to innovative products and services like Voyager and Pioneer trackers and "Golden Row" training. Carroll is the President of Powin.

08:13 EST Phio Pharmaceuticals announces exercise of warrants for $2.8M gross proceeds - Phio Pharmaceuticals announced the agreement by several accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 2,130,252 shares of common stock of the Company originally issued in October 2018 through June 2023, having exercise prices between $5.40 and $4.03 per share, at a reduced exercise price of $1.33 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 and Form S-3. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.8 million, prior to deducting placement agent fees and estimated offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The offering is expected to close on or about December 8, 2023, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

08:11 EST Kratos Defense demonstrates "100% interoperability success" usng DIFI standard - Kratos Defense & Security Solutions demonstrated 100% interoperability success at the first ever DIFI Plugfest where satellite solutions providers converged to test the interoperability of their Digital IF products. Founded under the auspices of the IEEE, the Digital IF Interoperability Consortium is an independent, international group of companies, organizations, and government agencies that have an interest in the interoperability of satellite ground system equipment. Its Digital IF/RF standard is intended to accelerate industry transformation beyond stove-piped, hardware-based systems to digital software-defined networks.

08:11 EST Genpact names Krista Bessinger Head of Investor Relations, Caitlin Blewett CMO - Genpact appointed Krista Bessinger Head of Investor Relations and Caitlin Blewett as Chief Marketing Officer, or CMO. Prior to joining Genpact, Bessinger served in several senior IR roles, including as head of IR and ESG functions for Twitter beginning with the company's IPO and leading to its acquisition in 2022. Preceding her tenure at Twitter, she was Senior Director, Investor Relations at Zynga, and Head of Financial Planning and Analysis for YouTube at Google. Earlier in her career, she was a sell-side research analyst at Bank of America Merrill Lynch. Blewett previously led Deloitte's Marketing Strategy Center of Excellence and its Digital Marketing and Marketing Communications divisions. She has held leadership roles at WPP and Publicis Groupe.

08:10 EST Cidara presents new preclinical data on drug-Fc conjugate candidate - Cidara Therapeutics announced the presentation of new preclinical data on its novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate candidate at the ESMO Immuno-Oncology Annual Congress. Cidara also presented new preclinical data on CBO421, its first-in-class CD73-targeting DFC. The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland. "We are thrilled to be presenting promising preclinical data on our novel multi-specific DFC in colorectal cancer for the first time at ESMO-IO this year," said Jeffrey Stein, Ph.D., president and chief executive officer at Cidara. "Dual inhibition of both CD73 and PD-1 checkpoint pathways with a single DFC contributed to significant tumor growth reduction, highlighting the potential clinical benefits of this first-in-class multi-specific inhibitor derived from our Cloudbreak platform." Title: Discovery of a Novel, Dual CD73 & PD-1 Targeting Multi-specific Drug Fc-Conjugate for the Treatment of Cancer. Key highlights: CD73/PD-1 DFC is a potent inhibitor of hCD73 and hPD-1; DFC reduced tumor growth by 56% at 1mg/kg and greater than70% at 3mg/kg doses; DFC demonstrated superior activity to a pembrolizumab biosimilar antibody and a matched CD73 DFC at 1/3 the dose of the respective monotherapies. Title: Discovery of CBO421, a First-in-Class Drug Fc-Conjugate, Targeting CD73 in Cancer. Key highlights: CBO421 is a potent, AMP-competitive inhibitor of CD73 that demonstrates a differentiated in vitro activity profile across several assays compared with small molecule and antibody inhibitors of CD73 in clinical development; The in vitro potency, multiple mechanisms of action, and favorable pharmacokinetics profile of CBO421 translated to antitumor efficacy in monotherapy and in combination with PD-1 therapy

08:09 EST IN8bio appoints Corinne Epperly to board of directors - IN8bio announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors. Dr. Epperly will serve on IN8bio's Compensation Committee as well as its Science & Technology Committee. She will work closely with the management team to provide guidance on strategic, operational, scientific, and clinical matters related to the Company's pipeline of gamma-delta T cell therapies. Before joining IN8bio, Dr. Epperly most recently served as the COO of CARGO Therapeutics.

08:08 EST Microbot Medical announces completion of GLP pre-clinical study - Microbot Medical announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model. The study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations. Target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endovascular Robotic Surgical System. "Today's announcement marks another important milestone for the Company, as we continue our transition from R&D and pre-clinical phase into the clinical, regulatory and pre-commercial phase," commented Harel Gadot, CEO. "We expect to submit our IDE application to the FDA soon and commence our pivotal human clinical study, completing our transition to a clinically stage company."

08:08 EST Satellogic and Uzma in 3-year geospatial capabilities pact in Southeast Asia - Uzma an energy and technology company and Satellogic a firm in sub-meter resolution Earth Observation EO data collection, announced a groundbreaking collaboration aimed to evolve the landscape of satellite imagery capabilities and geospatial services in Southeast Asia. The agreement includes leveraging a state-of-the-art EO satellite designed and manufactured by Satellogic that is planned to be launched in the second half of 2024 as "UzmaSAT-1" aboard a SpaceX Falcon 9 rocket, and extensive tasking access to the Satellogic constellation. Through its wholly owned subsidiary, Geospatial AI Sdn Bhd, Uzma will leverage access to high-temporal and high-resolution satellite imagery from Satellogic's commercial fleet of sub-meter resolution EO satellites, which is the largest in the world. Through this collaboration with Satellogic, Geospatial AI, a two-time recipient of the Smart Technology Innovation of the Year* award, positions itself to accelerate the development of valuable geospatial applications, providing actionable insights for a rapidly growing market.

08:07 EST Worksport expands factory production with additional assembly line - Worksport is announcing the completion of its second assembly line for its innovative hard-folding covers. The company believes it is in a significant advancement for sustainable automotive innovation, marking a pivotal moment in the Company's expansion strategy. This development follows the Company's impressive 2,399% year-over-year revenue growth in Q3 2023 vs 2022 due the recent new US National After Market customer, a testament to its production capabilities and market demand. In August 2023, Worksport began production, setting the stage for this momentous achievement. The completion of the second assembly line is a strategic step in fulfilling the substantial $16 million annual sales agreement recently announced. Steven Rossi, CEO of Worksport, expressed his pride in this progress, stating, "The completion of our second assembly line not only signifies our commitment to growth and innovation, but also our dedication to meeting our customers' needs and sales objectives. We are excited to see the impact this will have on our production capabilities and overall growth trajectory." To support this expansion, Worksport is actively increasing its staff, with the expectation of having both assembly lines fully operational by the end of this month. Worksport recently initiated the test phase for its COR portable energy storage system, anticipating updates on an Alpha release soon. This innovative system, along with the SOLIS solar cover, is designed to provide solar power to pickup trucks. Worksport is committed to keeping its stakeholders informed of the factory's development and future advancements.

08:07 EST Amneal Pharmaceuticals announces Ongentys licensing agreement - Amneal Pharmaceuticals and Bial announced a licensing agreement where Amneal will have exclusive rights to market and distribute Ongentys in the U.S. starting on December 18. Amneal expects to begin distribution of Ongentys in early 2024. The financial terms of the agreement were not disclosed, and any incremental expenses associated with this product are contemplated within Amneal's guidance.

08:04 EST Dare Bioscience announces FDA clearance of IND application for DARE-VVA1 - Dare Bioscience announced that the U.S. Food and Drug Administration, FDA, has cleared its investigational new drug, IND, application for DARE-VVA1, a novel intravaginal proprietary formulation of tamoxifen being developed as a non-hormonal treatment option for moderate to severe dyspareunia, a symptom of VVA associated with menopause. With the IND clearance from the FDA, Dare can begin planning for an anticipated Phase 2 randomized, double-blinded, placebo-controlled, dose-finding clinical study of DARE-VVA1. "Although localized estrogen therapy is effective in reducing the symptoms of VVA and is commonly prescribed, there remains a large unmet need for non-hormonal treatment options for symptoms of VVA for women who cannot or choose not to use estrogen-based products," said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. "While we do not plan to commence the Phase 2 study until after we secure additional capital, this IND clearance marks an important regulatory step for Dare that supports our strategic discussions as we advance our portfolio of innovative product candidates and strive to address some of women's most persistent unmet needs."

08:04 EST Global Indemnity suspends exploration of sale, increases board - Global Indemnity announced that it suspended the exploration of the sale or merger of Penn-America, Global Indemnity's insurance group, and Global Indemnity itself at this time. Saul Fox, Global Indemnity's Chairman, stated: "Our merger & acquisition market information that suggested we pursue a transaction at this time was not realized." Jay Brown, Global Indemnity's Chief Executive Officer, added: "Given the Company's debt-free balance sheet and strong reserve base, coupled with our enviable decades-long profitability, outstanding management team, and extensive national agent and broker network, Penn-America is well-positioned to achieve exceptional financial results for our owners." Global Indemnity also announced that it increased the size of its board to seven members to accommodate the designation of Fred Karlinsky to the board. Karlinsky is co-chair of Greenberg Traurig, LLP's global insurance practice.

08:03 EST Red Robin names Meghan Spuler as Chief People Officer, effective Dec. 11 - Red Robin Gourmet Burgers announced the completion of its best-in-class leadership team with the appointment of Meghan Spuler as Chief People Officer, effective Dec. 11. Spuler succeeds Mark Simpson, who joined the company as Interim Chief People Officer in May 2023. Simpson will remain in an advisory capacity until the transition is complete.

08:02 EST Hepion board approves strategic restructuring plan - Hepion Pharmaceuticals announced that its Board of Directors has approved a strategic restructuring plan with the objective of preserving capital by initially reducing operating costs by approximately 60% going forward. As a result, Hepion will incur a one-time restructuring charge of approximately $400 - $800 thousand that will be recorded in the fourth quarter of 2023.

08:01 EST Leidos deploys SkyLine-X ATM system in New Zealand - Leidos announced the successful deployment of its SkyLine-X Air Traffic Management system in collaboration with Airways New Zealand. The deployment marks a significant step forward in the continued delivery of safe and efficient air navigation services across the New Zealand airspace. The deployment replaces Airways New Zealand's existing domestic ATM platform with a new system featuring a virtual multi-channel architecture for resilience against common mode and cyclical failures. It also introduces a new surveillance tracker for enhanced safety, and an upgraded modeler that will help Airways move towards Trajectory Based Operations, which would increase air traffic throughput.

07:43 EST IES Holdings promotes Matthew Simmes to president - IES Holdings announced the promotion of Matthew Simmes to the position of President and COO of the Company. Mr. Simmes, who was appointed as COO of IES in December 2021, will continue to manage the operations of all four of the Company's operating segments, reporting directly to Jeff Gendell, the Company's Chairman and CEO.

07:38 EST Repligen sees year-end cash, cash equivalents $717M-$727M - Jason Garland, Chief Financial Officer at Repligen said, "The exchange of the majority of our 2024 Notes addresses their impending maturity and extends the duration of our debt. Combined with the new subscriptions, the Transactions strengthen our balance sheet and provide added flexibility as we continue to execute on our M&A and organic growth strategies. As a result of the Transactions, we are updating our year-end cash and cash equivalent guidance to $717 - $727 million, up from $455 - $465 million communicated in our third quarter of 2023 earnings call. The increase reflects the cash proceeds from the Subscription Transactions, net of fees, estimated expenses and the share repurchases associated with the Subscription Agreements. Any portion of the proceeds used to finance in part the settlement upon conversion or repurchase of the remaining 2024 Notes at or prior to maturity, will be in used in 2024."

07:35 EST Easterly Government Properties names chairman Darrell Crate as CEO - Easterly Government Properties announced that Darrell Crate, the co-founder and current chairman of the board, has been appointed as CEO, effective January 1, 2024. In connection with Crate's appointment, William Trimble, III will retire from his position as president and CEO of Easterly effective December 31, 2023. As co-founder of the company and executive chairman of the board, Crate has played a crucial role in the development and execution of its operational strategy since inception. His transition to CEO ensures the company's succession plan remains connected to Easterly's foundational mission and values. William Binnie, currently the company's lead independent director has been appointed chairman of the board of directors, effective January 1, 2024. Allison Marino, Easterly's current chief accounting officer, or CAO, will assume the roles of CFO and CAO.

07:34 EST Xilio Therapeutics initiates enrollment for Phase 1 combination trial of XTX101 - Xilio Therapeutics announced the initiation of enrollment for its Phase 1 clinical trial of XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab and reported updated monotherapy data from its ongoing Phase 1 clinical trial evaluating XTX101 in late-line patients with advanced and immuno-oncology refractory solid tumors. The data were presented at the European Society for Medical Oncology Immuno-Oncology Congress on December 7, 2023. Update from ongoing Phase 1: As of the data cutoff date of November 13, 2023, 36 patients with advanced solid tumors had been administered XTX101 monotherapy, including 18 patients at the recommended Phase 2 dose and schedule of 150 mg once every six weeks. Patients treated at the RP2D of 150 mg Q6W were heavily pre-treated, with 83% of patients receiving three or more lines of anti-cancer therapy and 56% previously treated with an immunotherapy. Preliminary Safety Data At the RP2D of 150 mg Q6W, 18 patients were evaluable for safety as of the data cutoff date: Safety data were consistent with previously reported results. XTX101 monotherapy was generally well-tolerated with treatment-related adverse events primarily Grade 1 or 2, and no patients discontinued treatment due to a TRAE. In addition, as previously reported, only one patient had a dose reduction due to an adverse event. The most common TRAE of any grade reported by investigators was fatigue. As previously reported, investigators reported only two Grade 3 TRAEs: Grade 3 TRAE of diarrhea, which occurred after two doses and resolved after five days without steroid use, and one Grade 3 TRAE of dermatitis. In addition, as previously reported, no Grade 4 or 5 TRAEs were reported by investigators across all dosing levels and dosing intervals. Preliminary Anti-Tumor Activity Data At the RP2D of 150 mg Q6W, 12 patients were evaluable for anti-tumor activity as of the data cutoff date: As previously reported, a confirmed partial response was observed in a patient with Stage 4 PD-L1 negative non-small cell lung cancer, including complete resolution of liver metastases. The confirmed PR continued through 36 weeks of treatment with XTX101, with the patient discontinuing treatment after week 36 due to an unrelated adverse event. Additional data reported today demonstrated a disease control rate of 33% in late-line and IO refractory patients administered XTX101 monotherapy at the RP2D of 150 mg Q6W, consisting of the confirmed PR in the NSCLC patient and stable disease in three patients. Preliminary Pharmacokinetic Data: As previously reported, consistent with the tumor-selective design for XTX101, preliminary pharmacokinetic analyses demonstrated 96% activation of XTX101 in a melanoma tumor and 73% activation in a metastatic liver lesion in a colorectal cancer patient, compared to minimal peripheral activation of XTX101 of 13% in both patients. Clinical Development Plans for XTX101: Xilio recently completed enrolling patients at the RP2D of 150 mg Q6W in monotherapy dose expansion and initiated enrollment in Phase 1 combination dose escalation to evaluate the safety, tolerability and efficacy of XTX101 in combination with atezolizumab. As previously reported, subject to obtaining sufficient additional capital, Xilio plans to: Complete Phase 1 combination dose escalation and select a RP2D for XTX101 in combination with atezolizumab in the second quarter of 2024 Subject to the results of Phase 1 combination dose escalation, initiate a Phase 2 trial to evaluate the safety and efficacy of XTX101 in combination with atezolizumab in patients with MSS CRC in the third quarter of 2024

07:32 EST Cytokinetics presents results from COURAGE-ALS study - Cytokinetics announced that the full results of COURAGE-ALS, were presented at the 34th International Symposium on ALS/MND. At the second interim analysis the Data Monitoring Committee recommended the discontinuation of the clinical trial due to futility. Subsequently, the Company concluded study conduct in March 2023 and discontinued treatment with reldesemtiv in all patients including those in the open-label extension study, COURAGE-ALS OLE. Development of reldesemtiv has been terminated. At the time of the discontinuation of COURAGE-ALS, 486 patients had started treatment with reldesemtiv or placebo and 276 had completed dosing through 24 weeks. Treatment with reldesemtiv for 24 weeks had no effect on the primary efficacy endpoint measure of change from baseline up to Week 24 in the ALS Functional Rating Scale Revised. Patients treated with reldesemtiv declined 5.3 points per month while patients treated with placebo declined 4.8 points per month. No pre-defined patient subgroup favored treatment with reldesemtiv. Patients with a faster disease progression rate did not experience a greater treatment effect from reldesemtiv, contrary to analyses conducted post hoc from FORTITUDE-ALS, the Phase 2 clinical trial of reldesemtiv, which had suggested that treatment effects were more evident in patients with a faster disease progression rate. Reldesemtiv also demonstrated no effect on key secondary endpoints including change from baseline to Week 24 in in-clinic percent predicted forced vital capacity, ALS Questionnaire 40 and handgrip strength. The incidence of serious adverse events in COURAGE-ALS was similar between the placebo group and the reldesemtiv group. The most common treatment-emergent adverse events were in system organ classes including respiratory, thoracic and mediastinal disorders, gastrointestinal disorders and infections and infestations. Overall, non-serious TEAEs also occurred at similar frequency between the placebo group and the reldesemtiv group. The only non-serious TEAE that differed between the placebo and reldesemtiv groups was abnormal laboratory investigations driven primarily by elevated transaminases, which occurred in 18.8% of patients treated with reldesemtiv and 11.8% of patients treated with placebo.

07:18 EST NioCorp appoints Deloitte & Touche as independent auditor - NioCorp Developments announced the appointment of Deloitte & Touche as the company's new independent registered public accounting firm, effective immediately. Deloitte replaces BDO USA, P.C., which elected not to stand for re-election at the Company's 2023 Annual General Meeting of Shareholders as the company's independent auditor.

07:16 EST Lithium Ionic reports results from drilling program at Salinas Lithium - Lithium Ionic reports results from the ongoing drilling program at the Salinas Lithium Project, located approximately 100 kilometres north of its Itinga group of properties which hosts the Feasibility-stage Bandeira lithium project and the Outro Lado lithium deposit. The Company is actively working towards establishing an initial NI 43-101 resource estimate at Salinas in 2024. With four drill rigs currently operating, the team is focused on continuing to test and delineate multiple outcropping spodumene-rich pegmatite bodies. Approximately 24,000 metres (99 holes) have been completed at Salinas since drilling began in May 2023.

07:15 EST Regeneron announces results from Phase 1/2 trial of linvoseltamab - Regeneron Pharmaceuticals announced that the primary endpoint analysis from the pivotal trial investigating linvoseltamab demonstrated high rates of deep and durable responses in patients with relapsed/refractory multiple myeloma. These Phase 1/2 results are planned to be submitted to regulatory authorities, including to the U.S. Food and Drug Administration this year. Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. At a median duration of follow-up of 11 months, an objective response rate of 71% as assessed by an independent review committee, with 46% achieving a complete response or better, was observed in patients treated with linvoseltamab 200 mg in the Phase 1/2 trial. After a minimum of 24 weeks of therapy, patients who achieved a very good partial response or better shifted from every two-week to every four-week dosing. These results build on an earlier data cut, with 8 months of median follow-up, that will be presented at the 65th American Society of Hematology Annual Meeting and Exposition from December 9 to 12 in San Diego, CA. Based on the latest data cut, all patients treated with 200 mg experienced an adverse event (AE), including 85% who experienced Grade greater than or equal to3 adverse events. The most commonly occurring AE was cytokine release syndrome. Of the CRS cases, the majority were Grade 1, 10% were Grade 2 and there was one case of Grade 3 CRS. Adjudicated immune effector cell-associated neurotoxicity syndrome events occurred in 9 patients; Grade 3 ICANS occurred in 3 patients, and no cases of greater than or equal toGrade 4 cases. All grade infections were observed in 73% of patients; 34% were Grade 3 or 4. Deaths due to treatment-emergent AEs on-treatment or within 30 days post last dose occurred in 14 patients, of which 11 (9%) were due to infections.

07:14 EST Canadian Solar's e-STORAGE to deliver battery storage solutions in the UK - Canadian Solar announced that e-STORAGE, which is part of the company's majority-owned subsidiary CSI Solar, has been awarded by Copenhagen Infrastructure Partners Flagship Funds, a supply and integration contract for a 500 MW / 1,170 MWh DC of energy storage solutions for its Coalburn 1 Project, in Scotland, UK. The Coalburn 1 project is set to become the largest battery storage project in the UK and is scheduled for installation by Q1 2025. The Coalburn 1 energy storage facility will use e-STORAGE's battery technology to store generated renewable energy and release it during peak power consumption demand, to support and stabilize the National Grid transmission network. e-STORAGE will deliver its proprietary SolBank battery energy storage systems and provide full integration, commissioning, and long-term operational services for the project.

07:13 EST Medtronic terminates agreement to acquire EOFlow - In a regulatory filing last night, the company stated: "On May 25, 2023, Medtronic plc announced that it had entered into a set of definitive agreements to acquire EOFlow Co. Ltd. (EOFlow) pursuant to a share purchase agreement, a share subscription agreement, and a public tender offer, subject to the satisfaction of the minimum tender condition and certain customary closing conditions, including receipt of required regulatory clearances. On December 6, 2023, based upon multiple breaches under the Agreements, Medtronic delivered notice to EOFlow that it had exercised its right to terminate the Agreements. Medtronic does not believe any termination fee is payable under the Agreements. The termination does not impact Medtronic's fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump."

07:11 EST Oncolytics' pelareorep shows efficacy in breast cancer study - Oncolytics announced the presentation of additional translational data from the AWARE-1 breast cancer window-of-opportunity study conducted in combination with SOLTI-Innovative Cancer Research at The San Antonio Breast Cancer Symposium. "Translational data presented from the AWARE-1 study at SABCS showed that pelareorep induced the expansion of tumor-infiltrating lymphocytes, or TILs, in matched tumor biopsy and peripheral blood samples of newly diagnosed breast cancer patients. In addition, sequencing of the T cell receptors showed a more prominent expansion of existing TIL clones in the blood. We consider these results to be positive and important because they build on additional translational results reported this fall at two other medical meetings...and provide further support for pelareorep's unique immunologic mechanism of action," said CEO Matt Coffey. "Taken together, these translational data affirm pelareorep's ability to enhance T cell infiltration into tumors and expand TILs in the peripheral blood, which have been correlated with tumor response. We intend to incorporate these learnings into the designs of our registrational studies in metastatic breast cancer and pancreatic cancer." CMO Heineman concluded, "Results from multiple prior studies lead us to believe that pelareorep has the potential to fill very important treatment gaps for both breast and pancreatic cancer patients. The translational data reported this fall emphasize the importance of TIL clone expansion in pelareorep-treated patients and represents an important area for further exploration. We believe that analysis of TIL clone expansion could become a helpful precision tool to provide an early indication of treatment response and serve as a potential guide to patient care with pelareorep. We remain dedicated to expeditiously advancing the clinical development of pelareorep in support of our goal to provide cancer patients with improved treatment options."

07:11 EST Ford, Resideo launch 'EV-Home Power Partnership' project - Ford (F) and Resideo Technologies (REZI) announced a joint simulation project to explore vehicle-to-home energy management called the "EV-Home Power Partnership," designed to explore the potential of electric vehicle batteries to support optimal home energy management. The project will explore, test and quantify the customer benefits of pairing bi-directional EV charging with a Resideo smart thermostat to help customers potentially save money on monthly electric bills, reduce strain on the U.S. electric grid and enable use of cleaner energy, while helping ensure homeowner comfort. The project is designed to assess how coordination of bi-directional EV and a smart thermostat can reduce the overall energy needed by the home during times of electric grid stress while minimizing energy usage during the most expensive hours each day by automating the home to match a consumers' Time-of-Use electricity rate. Additionally, it also will assess how the coordination between the battery and smart thermostat can enable a system to leverage cleaner energy from the grid if renewable energy is readily available.

07:10 EST TScan Therapeutics appoints Woods to board of directors - TScan Therapeutics (TCRX) announced the appointment of R. Keith Woods to its Board of Directors. Woods has over 30 years of life science experience, with expertise in commercialization, sales, global operations, supply chain and business strategy. Woods most recently as chief operating officer, COO, of argenx (ARGX) where he led the company through its transition from an R&D organization to a global commercial organization.

07:08 EST Climb Global announces expansion of GSA IT-70 contract with GFI Software - Climb Channel Solutions announced the expansion of their GSA IT-70 Contract with the addition of GFI Software, a leading software company with solutions for security, collaboration, and network management applications. GFI Software has been a strategic partner of Climb since 2019. With their cloud-based GFI AppManager platform, partners can manage all customers and products under one pane of view. "Climb is proud to offer our vendors the opportunity to leverage our government contracts, such as GSA to enable them to expand into the public sector without additional complications," says Dale Foster, CEO of Climb Channel Solutions. "We are excited to add GFI to our GSA contract to assist in the expansion of their business and bring their portfolio of network, security and communication management into the public sector."

07:06 EST Dorman Products releases hundreds of new products - Dorman Products is releasing 400 new motor vehicle parts this month, representing millions of new sales opportunities for automotive parts distributors, retailers, and repair shops. The new products further reinforce Dorman's position as a leading aftermarket provider of comprehensive powertrain repair solutions. This month's new releases include an innovative Dorman OE FIX exhaust manifold clamp repair kit with coverage for approximately 3 million select aging Ford and Lincoln vehicles. Dorman is also introducing a new OE FIX engine heater hose assembly, adding to a large and growing catalog of complex automotive hose assemblies.

07:05 EST Compass Pathways appoints Loxam as CFO - Compass Pathways announced that it has appointed Teri Loxam as Chief Financial Officer, CFO, effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO. Teri joins the company from Gameto, where she was CFO and played a pivotal role in negotiating multiple licensing agreements and helping to develop the regulatory and commercial strategy for their lead product.

07:04 EST CPI Card Group in share repurchase pact with majority shareholder Parallel49 - CPI Card Group announced that it has entered into an agreement to purchase shares of the Company's common stock from Tricor Pacific Capital Partners US, LP, a fund managed by Parallel49 Equity under the Company's previously announced $20M share repurchase authorization. Pursuant to the agreement, the Company has agreed to purchase from Parallel49, and Parallel49 has agreed to sell to the Company, a number of shares equal to three times the number of shares acquired by the Company in the open market from non-Parallel49 holders from time to time during the period December 11, 2023 through March 31 , up to a maximum of 325,000 shares. The purchase price for the shares to be acquired from Parallel49 will be equivalent to 98% of the volume weighted average purchase price of shares bought by the Company in the open market from non-Parallel49 holders during that time period, with settlement occurring within five days of the end of the period. The agreement has been approved by the Audit Committee of the Board of Directors of the Company.

07:03 EST Vanda Pharmaceuticals acquires U.S. and Canadian rights to PONVORY - Vanda Pharmaceuticals (VNDA) announced that it has acquired U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals, a Johnson & Johnson (JNJ) company. PONVORY is approved by the U.S. FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. PONVORY has a proven safety profile with over 10 years of data.

06:58 EST Dollar General sees FY23 CapEx $1.6B-$1.7B - Sees 3,110 real estate projects in the United States, including 990 new store openings, 2,000 remodels, and 120 store relocations in FY23.

06:48 EST Merck discontinues trial evaluating Keytruda combination in NSCLC - Merck will stop the Phase 3 KEYLYNK-008 trial evaluating Keytruda, Merck's anti-PD-1 therapy, in combination with maintenance Lynparza, a PARP inhibitor, for the treatment of patients with metastatic squamous non-small cell lung cancer, or NSCLC. Merck is discontinuing the study based on the recommendation of an independent Data Monitoring Committee. At the interim analysis 3, Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not demonstrate an improvement in overall survival, one of the study's dual primary endpoints, compared to Keytruda in combination with chemotherapy followed by Keytruda plus placebo. The study's other dual primary endpoint, progression-free survival, was not statistically significant at the second interim analysis, but there was a numerical improvement compared to the control arm. The safety profile in this trial was consistent with that observed in previously reported studies for the individual therapies and no new safety signals were identified.

06:35 EST Oculis announces FPFV in Phase 2b RELIEF trial of licaminlimab - Oculis announces First Patient First Visit in its Phase 2b RELIEF trial evaluating the potential of licaminlimab, Oculis' innovative anti-TNFalpha biologic eye drop, for the treatment of Dry Eye Disease. 120 patients are planned to be randomized to either licaminlimab or vehicle for a 6-week treatment and a 2-week follow up period. Topline results are anticipated in mid-2024.

06:32 EST Lightbridge, Centrus Energy enter contract to conduct feed study - Lightbridge (LTBR) and Centrus Energy (LEU) announced a contract to conduct a front-end engineering and design, or FEED, study to add a dedicated Lightbridge Pilot Fuel Fabrication Facility, or LPFFF, at the American Centrifuge Plant in Piketon, Ohio. The FEED study will identify infrastructure and licensing requirements as well as the estimated cost and construction schedule for the LPFFF. Centrus' wholly-owned subsidiary, American Centrifuge Operating, will lead the study, which is expected to be completed in 2024.

06:21 EST Sanofi says Sarclisa Phase 3 trial met primary endpoint - The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa in combination with standard-of-care bortezomib, lenalidomide and dexamethasone met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free survival, or PFS, compared with VRd alone in transplant-ineligible patients with newly diagnosed multiple myeloma, Sanofi announced. "This is also the second Phase 3 trial investigating Sarclisa in newly diagnosed patients to show superiority versus standard of care," the company said. The safety and tolerability of Sarclisa observed in this trial was consistent with the established safety profile of Sarclisa and VRd. Study results will be submitted for presentation at an upcoming medical meeting and form the basis of a future regulatory submission.

06:11 EST Meta Platforms launches default end-to-end encryption on Messenger - Meta announces that it is rolling out default end-to-end encryption for personal messages and calls on Messenger and Facebook, as well as a suite of new features to further control users' messaging experience. Since 2016, Messenger has had the option for people to turn on end-to-end encryption, but Meta is now changing private chats and calls across Messenger to be end-to-end encrypted by default. This means that nobody, including Meta, can see what's sent or said. "End-to-end encryption gives people more secure chats in Messenger. These chats will not only have all of the things people know and love, like themes and custom reactions, but also a host of new features we know are important for our community. These new features will be available for use immediately" Loredana Crisan, Head of Messenger said. Reference Link

06:08 EST Hooker Furniture expects growth initiatives to 'gain traction' in 1H24 - "While economic indicators remain mixed and furniture industry retail traffic is down about 15% from January through October 2023, we believe the long-term economic outlook has improved which bodes well for Hooker and the industry," said CEO Hoff. "Reduced housing activity and high mortgage interest rates are still challenging, but several positives have emerged since last quarter. Core inflation is at the lowest level since 2021, the US economy grew nearly 5% last quarter, unemployment remains at record lows and a recession appears less likely. "As mentioned earlier, current retail conditions are soft, but consolidated orders are up $12.7 million, or 15.7% for the third quarter. For the first nine months, consolidated orders increased by $75.8 million or 33.5%," Hoff said. "As we look to the next quarter, we see flat sales for our higher-priced Hooker Legacy brands as compared to the prior year fourth quarter. We expect that the current downturn in the furniture retail business will temporarily suppress sales growth at HMI through the fourth quarter. However, significant new retail product placements achieved by HMI recently should begin to buoy sales by the first quarter of next fiscal year as the placements generate orders and backlogs. We believe a lot of our growth initiatives will begin to gain traction in the first half of calendar 2024. We believe that our focus on reducing costs, keeping our balance sheet strong and judiciously deploying capital, along with our investments to promote higher visibility and future growth will continue to put us in the strongest possible position to leverage a return of furniture demand to more typical levels," Hoff concluded.

06:04 EST Li-Cycle comments on strategic alternatives process - Li-Cycle acknowledged regulatory filings made yesterday in the United States and Canada by Glencore plc and its affiliates related to discussions that Glencore is having regarding Li-Cycle and its subsidiaries, in light of the ongoing process being conducted by the company to evaluate financing and strategic alternatives. The company does not intend to comment specifically on Glencore's disclosures. As previously announced on November 13, 2023, the company has engaged Moelis & Company as financial advisor to assist in evaluating financing and strategic alternatives for the company. Moelis has commenced a robust process that includes both existing stakeholders and potential new investors. The company is committed to identifying and pursuing financing and strategic alternatives that are in the best interests of Li-Cycle.

05:20 EST Hansa Biopharma announces data from the 15-HMedIdeS-09 trial - Hansa Biopharma announced high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in disease-related efficacy measures. Further analysis of efficacy data will be conducted in 2024. 15-HMedIdeS-09 is an open-label, single arm, trial evaluating the safety, tolerability and efficacy of imlifidase in GBS patients in combination with standard of care, or SoC, intravenous immunoglobulin, or IVIg. Further analysis will contextualize efficacy data from the single arm 15-HMedIdeS-09 study through a comparison to data from patients receiving standard of care treatment in the International Guillain-Barre Syndrome Outcome Study, or IGOS, database. This analysis is expected to be completed and communicated in 2024.

05:07 EST Gravitas Education announces plan to close mergers, transfer to NYSE - Gravitas Education announced that the transaction parties have received all necessary regulatory approvals related to the merger transaction by and among the company, NetDragon Websoft and Elmtree, a Cayman Islands exempted company limited by shares wholly owned by Best Assistant. All conditions precedent to closing have been satisfied, and the transaction parties will proceed with the closing of the merger. As previously announced, a special cash dividend of $5.628 per American depositary share, or $0.5628 per ordinary share, will be payable on or before the 21st day after the date of closing to shareholders of record at the close of business in the Cayman Islands and holders of ADSs at the close of business in New York on December 11. The aggregate amount of cash dividends to be paid is approximately $16M. In order to retain the right to the cash dividend, ADS holders of the company need to hold the ADSs until the ex-dividend date, which shall be the first business day after the closing. The company also announced that it has entered into a second omnibus amendment and waiver, pursuant to which the transaction parties have agreed, among other things, to change the acceptable listing venue of the company, to amend certain condition precedent to closing and to amend and waive certain condition precedent to the sale of the Company's shares by certain existing shareholders of the company pursuant to a share purchase agreement dated April 18, as amended, to NetDragon. Pursuant to the second amendment agreement, the transaction parties have agreed that in addition to New York Stock Exchange, NYSE American and any tier of the Nasdaq Stock Market are also the qualified stock exchanges on which the company may be listed in connection with the merger. The company further announced that it will transfer the listing of its ADSs from the NYSE to NYSE American upon completion of the merger. The company has received the approval for listing from the staff of the NYSE American on December 6. The company expects to begin trading on the NYSE American on or about December 13 under the new name "Mynd.ai, Inc." and the new ticker symbol of "MYND". Before that, the company will continue to trade on NYSE under its current ticker symbol "GEHI".